UCHL1 loss alters the cell cycle in metastatic pancreatic neuroendocrine tumors

Brendan M. Finnerty, Maureen D. Moore, Akanksha Verma, Anna Aronova, Shixia Huang, Dean P. Edwards, Zhengming Chen, Marco Seandel, Theresa Scognamiglio, Yi Chieh Nancy Du, Olivier Elemento, Rasa Zarnegar, Irene M. Min, Thomas J. Fahey

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Loss of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) expression by CpG promoter hypermethylation is associated with metastasis in gastroenteropancreatic neuroendocrine tumors; however, the mechanism of how UCHL1 loss contributes to metastatic potential remains unclear. In this study, we first confirmed that the loss of UCHL1 expression on immunohistochemistry was significantly associated with metastatic tumors in a translational pancreatic neuroendocrine tumor (PNET) cohort, with a sensitivity and specificity of 78% and 89%, respectively. To study the mechanism driving this aggressive phenotype, BON and QGP-1 metastatic PNET cell lines, which do not produce UCHL1, were stably transfected to re-express UCHL1. In vitro assays, RNA sequencing and reverse phase protein array (RPPA) analyses were performed comparing empty-vector negative controls and UCHL1-expressing cell lines. UCHL1 re-expression is associated with lower anchorage-independent colony growth in BON cells, lower colony formation in QGP cells and a higher percentage of cells in the G0/G1 cell-cycle phase in BON and QGP cells. On RPPA proteomic analysis, there was an upregulation of cell-cycle regulatory proteins CHK2 (1.2-fold change, P = 0.004) and P21 (1.2-fold change, P = 0.023) in BON cells expressing UCHL1; western blot confirmed upregulation of phosphorylated CHK2 and P21. There were no transcriptomic differences detected on RNA sequencing between empty-vector negative controls and UCHL1-expressing cell lines. In conclusion, UCHL1 loss correlates with metastatic potential in PNETs and its re-expression induces a less aggressive phenotype in vitro, in part by inducing cell-cycle arrest through posttranslational regulation of phosphorylated CHK2. UCHL1 expression should be considered as a functional biomarker in detecting PNETs capable of metastasis.

Original languageEnglish (US)
Pages (from-to)411-423
Number of pages13
JournalEndocrine-Related Cancer
Issue number4
StatePublished - 2018


  • Cell cycle
  • Metastasis
  • Pancreatic neuroendocrine tumors
  • UCHL1

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research


Dive into the research topics of 'UCHL1 loss alters the cell cycle in metastatic pancreatic neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this